Cover Image
市場調查報告書

疤痕:開發中產品分析

Scar - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 199796
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
疤痕:開發中產品分析 Scar - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 90 Pages
簡介

疤痕是覆蓋在傷口上,永久性的皮膚貼片。疤痕產生於組織受損部位,為由紅到紫的堅硬纖維組織,厚度與顏色會隨著時愈來愈淡薄。

本報告提供疤痕治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

疤痕概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

大學/研究機關研究中的產品

開發治療藥的企業

  • 3M Drug Delivery Systems
  • Albireo AB
  • Altacor Limited
  • Beech Tree Labs, Inc.
  • Clanotech AB
  • Escape Therapeutics, Inc.
  • FirstString Research, Inc.
  • LegoChem Biosciences, Inc
  • Moerae Matrix, Inc.
  • Promore Pharma
  • RXi Pharmaceuticals Corporation
  • VBS Pharmaceuticals

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8406IDB

Summary

Global Markets Direct's, 'Scar - Pipeline Review, H2 2016', provides an overview of the Scar pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Scar
  • The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Scar therapeutics and enlists all their major and minor projects
  • The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Scar

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Scar
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Scar Overview
  • Therapeutics Development
    • Pipeline Products for Scar - Overview
    • Pipeline Products for Scar - Comparative Analysis
  • Scar - Therapeutics under Development by Companies
  • Scar - Therapeutics under Investigation by Universities/Institutes
  • Scar - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Scar - Products under Development by Companies
  • Scar - Products under Investigation by Universities/Institutes
  • Scar - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Albireo AB
    • Altacor Limited
    • Beech Tree Labs, Inc.
    • Clanotech AB
    • Escape Therapeutics, Inc.
    • FirstString Research, Inc.
    • LegoChem Biosciences, Inc
    • Moerae Matrix, Inc.
    • Promore Pharma
    • RXi Pharmaceuticals Corporation
    • VBS Pharmaceuticals
  • Scar - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-3914 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-5425 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTL-slo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLT-28643 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FibroStem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Granexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICX-RHY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-030110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMI-0100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nefopam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide for Wounds and Scars - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXL-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-34240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tranilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Scar - Dormant Projects
  • Scar - Discontinued Products
  • Scar - Product Development Milestones
    • Featured News & Press Releases
      • Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
      • Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
      • Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
      • Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
      • Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
      • Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
      • Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
      • Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
      • Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
      • Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
      • Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
      • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
      • Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
      • Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
      • Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Scar, H2 2016
  • Number of Products under Development for Scar - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Scar - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Scar - Pipeline by Albireo AB, H2 2016
  • Scar - Pipeline by Altacor Limited, H2 2016
  • Scar - Pipeline by Beech Tree Labs, Inc., H2 2016
  • Scar - Pipeline by Clanotech AB, H2 2016
  • Scar - Pipeline by Escape Therapeutics, Inc., H2 2016
  • Scar - Pipeline by FirstString Research, Inc., H2 2016
  • Scar - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Scar - Pipeline by Moerae Matrix, Inc., H2 2016
  • Scar - Pipeline by Promore Pharma, H2 2016
  • Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Scar - Pipeline by VBS Pharmaceuticals, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Scar - Dormant Projects, H2 2016
  • Scar - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Scar, H2 2016
  • Number of Products under Development for Scar - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top